Enzyme Kinetics and Diagnostic Enzymology

Clinical enzyme assays measure reaction rates under defined conditions. Substrate concentration, pH, temperature, cofactors, reaction direction, and the detection system all shape the reported activity. Interpretation therefore begins with the measurement procedure, then adds the enzyme’s tissue distribution, specimen quality, and the pattern formed with related tests.

Enzyme structure and classification

An enzyme binds its substrate at an active site and lowers the activation energy needed to reach the reaction’s transition state. Binding commonly changes the shape of the active site through induced fit. Some enzymes also have an allosteric site where another molecule changes catalytic activity. The amino acids that form one active site can come from different regions of one polypeptide or from different subunits of a multimeric enzyme. Enzyme specificity ranges from a single substrate to a group of related substrates or one type of chemical bond.

Many enzymes require a nonprotein component:

• An activator is an inorganic ion needed for activity, such as magnesium or zinc.
• A coenzyme is an organic participant, often derived from a vitamin. A tightly bound coenzyme is a prosthetic group.
• An apoenzyme is the protein portion alone. The active enzyme with its required component is the holoenzyme.
• A zymogen is an inactive precursor that becomes active after a biochemical change, commonly proteolytic cleavage. This delays activity until the enzyme reaches the proper tissue or pathway.

The International Union of Biochemistry and Molecular Biology assigns a four-part Enzyme Commission (EC) number that identifies class, subclass, sub-subclass, and the enzyme’s serial entry. The current system has seven major classes.¹

Multiple enzyme forms. Isoenzymes, also called isozymes, are genetically determined forms that catalyze the same reaction and differ in primary structure. Electrophoretic mobility, heat stability, inhibitor response, and antibody recognition can separate them. Post-translationally modified forms, zymogens, polymers, and enzyme-protein complexes are other molecular forms and require more specific names.²

Reaction rates

For a simple one-substrate reaction, enzyme and substrate form a reversible complex before product is released:

E + S ⇌ ES → E + P

At low substrate concentration, reaction velocity rises nearly in proportion to substrate concentration. As active sites become occupied, the rate approaches a maximum velocity, V_max. Michaelis-Menten kinetics describe this relationship:

v = (V_max × [S]) ÷ (K_m + [S])

In this ideal model, K_m is the substrate concentration at one-half V_max. A lower K_m often indicates greater apparent substrate affinity under the same model and assay conditions. K_m and a binding dissociation constant coincide only under restricted kinetic conditions.³

Worked example. An enzyme has a V_max of 160 U/L and a K_m of 5.0 mmol/L. At [S] = 15.0 mmol/L:

v = (160 × 15) ÷ (5 + 15) = 120 U/L

The measured rate is 75% of V_max.

The historical Lineweaver-Burk plot graphs 1/v against 1/[S]:

1/v = (K_m/V_max)(1/[S]) + 1/V_max

The y-intercept is 1/V_max, the x-intercept is −1/K_m, and the slope is K_m/V_max. Reciprocal transformation gives disproportionate weight to observations at low substrate concentration, so direct nonlinear fitting of the Michaelis-Menten curve is generally preferred.

Idealized inhibition patterns

The classic inhibition patterns describe simplified steady-state models. Real enzymes can show additional binding and regulatory behavior.³

Temperature, pH, ionic strength, reaction time, substrate concentration, and cofactor concentration also change activity. The validated procedure defines each condition. Many higher-order reference procedures for common clinical enzymes operate at 37°C, while routine results remain traceable only to their stated measurement procedure.⁴

Measuring catalytic activity

Enzyme activity assays usually measure the initial linear reaction rate while substrate and required cofactors are present in sufficient excess. Excessive substrate depletion, product accumulation, inhibitor carryover, or departure from the method’s linear range can lower the apparent activity. The analyzer follows the reaction directly or links it to an indicator reaction whose product can be measured.

When substrate concentration is well below K_m, the reaction is approximately first order with respect to substrate. When substrate is saturating, the reaction is approximately zero order with respect to substrate, and the rate depends chiefly on enzyme amount. Activity assays use this saturating region so the specimen enzyme controls the measured rate.

NADH and NADPH absorb strongly near 340 nm, while their oxidized forms have little absorbance there. Many coupled methods therefore follow a rise or fall in absorbance at 340 nm. Other assays use a colored substrate or couple the reaction to a dye measured at another wavelength.

The unit (U) is the catalytic activity that converts 1 µmol of substrate per minute under the specified conditions. The coherent SI unit is the katal (kat), equal to 1 mol/s. BIPM specifies that a katal result must identify the measurement procedure and indicator reaction.⁵

1 U = 1 µmol/min = 16.67 nmol/s = 16.67 nkat

Worked conversion. A creatine kinase activity of 240 U/L equals:

240 ÷ 60 = 4.0 µmol·s⁻¹·L⁻¹ = 4.0 µkat/L = 4,000 nkat/L

Activity results depend on reaction conditions even when laboratories report the same unit. IFCC higher-order procedures and reference materials support traceability for several enzyme measurands. Routine procedures can still differ in substrate, cofactor activation, calibration, and response to molecular forms.⁴

The absorbance calculation behind these measurements appears in Core Chemistry Calculations. Enzymes are also used as reagents in assays for glucose, cholesterol, triglycerides, and uric acid, and as labels that amplify signals in immunoassays.

Reference intervals and specimen rules

Each laboratory applies the reference interval verified for its patient population, specimen, and method. Under CLIA, a laboratory verifies applicable manufacturer performance specifications before reporting patient results from an unmodified cleared or approved test system. It establishes the applicable specifications when it modifies a test, uses an unapproved method, develops a method in house, or lacks suitable manufacturer specifications. Reference intervals are among the specifications addressed when applicable.⁶

The same method-specific rule applies to specimen type, storage, hemolysis, lipemia, icterus, linearity, dilution, and reporting limits. A universal enzyme interval or specimen correction would hide clinically important differences among procedures.

Creatine kinase and lactate dehydrogenase

Creatine kinase

Creatine kinase (CK) transfers phosphate between creatine and adenosine triphosphate:

Creatine + ATP ⇌ phosphocreatine + ADP

CK activity is greatest in skeletal muscle, cardiac muscle, and brain. Total serum CK is used to evaluate and monitor muscle injury. Exercise, intramuscular injections, surgery, seizures, trauma, medications, muscle mass, age, and sex can change the result. A current coupled procedure runs the reaction toward ATP formation, then uses hexokinase and glucose-6-phosphate dehydrogenase to form NADPH for photometric measurement.⁷

Common laboratory definitions of rhabdomyolysis include CK greater than 5 times the upper reference limit or greater than 1,000 U/L. Serial measurements establish the peak and subsequent decline, with interpretation tied to muscle injury, kidney function, urine findings, and the local clinical protocol.⁸

CK-MB activity fractions and isoform ratios are historical myocardial infarction markers. Current acute coronary syndrome guidance identifies cardiac troponin, preferably a high-sensitivity assay, as the biomarker of choice. A troponin value above the assay’s 99th-percentile upper reference limit indicates myocardial injury, and serial change supports classification of an acute process.⁹

Significant hemolysis can interfere with CK measurement. The analyzer’s hemolysis limit and reagent design determine whether the specimen can be reported.⁷

Lactate dehydrogenase

Lactate dehydrogenase is commonly abbreviated LD in laboratory reporting and LDH in clinical prose. It catalyzes the reversible reaction:

Lactate + NAD⁺ ⇌ pyruvate + NADH + H⁺

A procedure can follow NADH formation in the lactate-to-pyruvate direction or NADH consumption in the reverse direction. Reaction direction and substrate concentration are part of the method. LD occurs throughout the body, including erythrocytes, liver, heart, skeletal muscle, kidney, and lung, so total activity has broad sensitivity and limited tissue specificity.¹⁰

Five cytosolic isoenzymes are tetramers of heart-type H and muscle-type M subunits:

Electrophoresis separates these fractions. Tissue associations overlap, so an isoenzyme pattern narrows possible sources without identifying one organ by itself.¹¹

An LD-1 activity greater than LD-2 was historically called a flipped pattern and was used in late myocardial infarction evaluation. Hemolysis and megaloblastic processes can produce the same pattern. Cardiac troponin now carries the cardiac-injury role.⁹¹¹

Erythrocytes contain abundant LD. Even modest in vitro hemolysis can increase serum or plasma activity and alter an isoenzyme pattern. Separation time, storage temperature, and rejection limits follow the performing method.¹⁰¹¹

Hepatobiliary and bone enzyme patterns

AST, ALT, ALP, GGT, and 5′-nucleotidase are markers of tissue injury, enzyme induction, or cholestasis. They are distinct from hepatic function measurements such as albumin and clotting-factor activity. Aminotransferase magnitude alone is an unreliable measure of the extent of liver injury.¹²

Aminotransferases

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) transfer amino groups with pyridoxal-5′-phosphate as a coenzyme:

Aspartate + 2-oxoglutarate ⇌ oxaloacetate + glutamate

Alanine + 2-oxoglutarate ⇌ pyruvate + glutamate

Kinetic AST methods commonly couple oxaloacetate reduction to malate dehydrogenase. ALT methods couple pyruvate reduction to LD. Both follow NADH consumption near 340 nm. Reagents can include pyridoxal-5′-phosphate activation, which changes measured activity and affects comparison among methods.¹³¹⁴

ALT has its greatest tissue concentration in the liver and is more liver specific than AST. AST also occurs in skeletal muscle, cardiac muscle, erythrocytes, kidney, and other tissues. Hemolysis and muscle injury can therefore increase AST with a smaller ALT response. A hepatocellular pattern has AST and ALT increased out of proportion to ALP; a cholestatic pattern has ALP increased out of proportion to the aminotransferases. The AST:ALT ratio can contribute to interpretation, while etiology requires the remaining laboratory and clinical findings.¹⁵

Alkaline phosphatase, GGT, and 5′-nucleotidase

Alkaline phosphatase (ALP) hydrolyzes phosphate monoesters under alkaline assay conditions. Colorimetric methods commonly use p-nitrophenyl phosphate, with pH, cofactors, wavelength, and calibration specified by the reagent system. Liver and bone supply most clinically important serum ALP activity. Intestinal and placental forms can also contribute.

Age and sex are needed for interval selection because osteoblastic activity during skeletal growth raises ALP in childhood and adolescence. Pregnancy can add placental ALP. When total ALP is increased, electrophoresis can separate liver, bone, and intestinal fractions, while specialized methods can measure bone-specific ALP.¹⁶

Gamma-glutamyl transferase (GGT) transfers a gamma-glutamyl group to an acceptor. Routine kinetic methods use a synthetic donor and a chromogenic product. Serum GGT primarily reflects the hepatobiliary system, although kidney tissue has high enzyme activity. An increased GGT accompanying increased ALP supports a hepatobiliary source; a normal GGT points toward bone or another source. Enzyme-inducing drugs and alcohol exposure can increase GGT, which limits its specificity. Current liver guidance uses GGT as a clarifying test for ALP source and avoids isolated GGT as a general screening result.¹⁵¹⁷

Serum 5′-nucleotidase hydrolyzes 5′-nucleotides. Increased activity can support a hepatobiliary source for an ALP increase because bone disease generally leaves 5′-nucleotidase within its method-specific interval. Availability, specimen type, anticoagulant acceptance, and interference limits vary by procedure.¹⁸

The connected bilirubin and urobilinogen patterns appear in Heme Synthesis, Porphyrias, and Bilirubin.

Acid phosphatase

Prostatic acid phosphatase was used historically in prostate cancer evaluation. Prostate-specific antigen now provides the principal blood marker used to screen selected patients, evaluate prostate symptoms, and monitor diagnosed disease. Acid phosphatase retains only limited specialized use.¹⁹

Pancreatic enzymes

Amylase and lipase are used to evaluate pancreatic injury. Diagnosis of acute pancreatitis requires at least two of three findings: characteristic pain, serum amylase or lipase at least 3 times the assay’s upper limit of normal, and characteristic imaging. Lipase is generally preferred because it has greater pancreatic specificity and remains increased longer.²⁰

Amylase

Alpha-amylase hydrolyzes internal alpha-1,4 glycosidic bonds in starch and related polysaccharides. Pancreas and salivary glands supply the main circulating forms. Current activity methods use defined chromogenic oligosaccharides, sometimes with coupling enzymes, and measure product formation as a rate. Substrate, calcium dependence, accepted anticoagulants, and wavelength vary by method. Historical amyloclastic methods followed loss of the starch-iodine color, while saccharogenic methods measured reducing sugars.²¹

Amylase can rise within hours of acute pancreatic injury and often returns toward baseline within 3 to 5 days. Renal impairment, salivary disease, abdominal disease, and macroamylasemia can also increase serum activity. Hypertriglyceridemia can suppress some amylase methods. Pancreatic and salivary isoamylase measurement can help identify the source of a persistent or discordant result. ²¹

Macroamylase is a high-molecular-mass complex with reduced renal clearance. A pattern of persistently increased serum amylase with relatively low urine amylase can support its presence. Paired clearance calculations and cutoffs remain method specific.²¹

Lipase

Pancreatic lipase hydrolyzes triglycerides. Activity depends on an appropriate emulsified substrate, and many methods add colipase and a bile salt or detergent to improve the pancreatic response. Assays use colorimetric or turbidimetric designs. The specific substrate and indicator reaction determine the wavelength and interference profile.²²

Lipase commonly rises within hours of acute pancreatitis and remains increased longer than amylase. Kidney disease and reduced clearance can raise lipase without acute pancreatic injury. Gross hemolysis and other specimen effects follow the assay’s stated limits. Serial enzyme magnitude alone is an unreliable measure of pancreatitis severity.²²

Other measured enzyme activities

ACE is a zinc-dependent peptidase that forms angiotensin II from angiotensin I and inactivates bradykinin. Activity methods use synthetic peptide substrates. Increased serum activity can occur in sarcoidosis and several other disorders, while ACE-inhibitor treatment can markedly suppress the result. The assay remains an adjunct interpreted with the diagnostic evaluation.²³

Diagnostic G6PD measurement uses erythrocytes in whole blood and commonly follows NADPH production near 340 nm. Serum and erythrocyte G6PD are different measurands, so an erythrocyte reference interval does not apply to serum. The full phenotypic and hematologic interpretation appears in Hemolytic and Hypoproliferative Anemias, Erythrocytosis, and Hemoglobin Variants.²⁴

Macroenzymes

A macroenzyme is a high-molecular-mass form whose size slows clearance and can produce persistent serum activity. Type 1 macroenzymes are commonly enzyme-immunoglobulin complexes. Type 2 forms include enzyme complexes with lipoproteins or other nonimmunoglobulin partners and self-polymerized enzyme. Macroforms have been reported for amylase, AST, ALT, ALP, GGT, CK, LD, lipase, and other activities.²⁵

A persistent, stable increase in a single enzyme without corresponding tissue injury suggests a macroenzyme. The macroform can respond differently from the free enzyme in an activity assay, so the size of the increase depends on the method.

Polyethylene glycol (PEG) precipitation is a common first screen. PEG removes immunoglobulins and some associated enzyme activity; the laboratory compares activity before and after precipitation. The result requires an enzyme-specific limit validated for the local PEG protocol, analyzer, age group, and population. A universal percentage cutoff is unsuitable. Electrophoresis, gel filtration, ultrafiltration, or immunochemical studies can characterize an unresolved form.²⁵

References

1. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Enzyme Nomenclature. Accessed August 29, 2026.
2. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Multiple Forms of Enzymes. Accessed August 29, 2026.
3. International Union of Biochemistry and Molecular Biology. Recommendations on Biochemical and Organic Nomenclature, Symbols and Terminology: Enzyme Kinetics. Accessed August 29, 2026.
4. Joint Committee for Traceability in Laboratory Medicine. Enzyme reference measurement procedures and materials. Accessed August 29, 2026.
5. Bureau International des Poids et Mesures. Resolution 12 of the 21st CGPM: Special name for the SI derived unit mole per second, the katal, for the expression of catalytic activity. 1999. doi:10.59161/CGPM1999RES12E.
6. Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C: Survey Procedures and Interpretive Guidelines for Laboratories and Laboratory Services. Rev 236. Issued January 23, 2026. Accessed August 29, 2026.
7. Mayo Clinic Laboratories. Creatine Kinase (CK), Serum. Accessed August 29, 2026.
8. Kodadek L, Carmichael SP II, Seshadri A, et al. Rhabdomyolysis: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document. Trauma Surg Acute Care Open. 2022;7(1):e000836. doi:10.1136/tsaco-2021-000836.
9. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/j.jacc.2024.11.009.
10. Mayo Clinic Laboratories. Lactate Dehydrogenase (LDH), Serum. Accessed August 29, 2026.
11. Labcorp. Lactate Dehydrogenase (LD) Isoenzymes. Accessed August 29, 2026.
12. Rosario D. How to approach elevated liver enzymes? American Association for the Study of Liver Diseases. January 17, 2025. Accessed August 29, 2026.
13. Mayo Clinic Laboratories. Aspartate Aminotransferase (AST) (GOT), Serum. Accessed August 29, 2026.
14. Mayo Clinic Laboratories. Alanine Aminotransferase (ALT) (GPT), Serum. Accessed August 29, 2026.
15. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18-35. doi:10.1038/ajg.2016.517.
16. Mayo Clinic Laboratories. Alkaline Phosphatase, Total and Isoenzymes, Serum. Accessed August 29, 2026.
17. Mayo Clinic Laboratories. Gamma-Glutamyltransferase, Serum. Accessed August 29, 2026.
18. Mayo Clinic Laboratories. 5′-Nucleotidase, Serum. Accessed August 29, 2026.
19. National Cancer Institute. Prostate-Specific Antigen Test. Updated January 31, 2025. Accessed August 29, 2026.
20. Tenner S, Vege SS, Sheth SG, et al. American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol. 2024;119(3):419-437. doi:10.14309/ajg.0000000000002645.
21. Mayo Clinic Laboratories. Amylase, Total, Serum. Accessed August 29, 2026.
22. Mayo Clinic Laboratories. Lipase, Serum. Accessed August 29, 2026.
23. Mayo Clinic Laboratories. Angiotensin Converting Enzyme, Serum. Accessed August 29, 2026.
24. Mayo Clinic Laboratories. Glucose 6-Phosphate Dehydrogenase Enzyme Activity, Blood. Accessed August 29, 2026.
25. Dedeene L, Stockman M, Steels S, Vermeersch P, Frans G. Detection of macroenzymes: establishing upper reference limits for eight enzymes after polyethylene glycol precipitation. Biochem Med (Zagreb). 2023;33(1):010705. doi:10.11613/BM.2023.010705.